Dupixent (dupilumab) is one of the most widely prescribed biologic medications in the United States. Doctors use it to treat ...

Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

Sanofi and Regeneron’s Dupixent has scored in a second phase 3 study in chronic obstructive pulmonary disease (COPD), setting up the monoclonal antibody to become the first biologic to treat the lung ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) ...

The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept ...

Since its initial approval for moderate-to-severe atopic dermatitis, Dupixent has secured approvals across eight other diseases, including severe chronic rhinosinusitis with nasal polyposis, severe ...